Objective Patients treated for nonfunctioning pituitary macroadenoma (NFMA) with suprasellar extension show disturbed sleep characteristics, possibly related to hypothalamic dysfunction. In addition to hypopituitarism, both structural hypothalamic damage and sleep restriction per se are associated with the metabolic syndrome. However, the prevalence of the metabolic syndrome in patients with NFMA is not well established. Our objective was to study the prevalence and risk factors for (components of) the metabolic syndrome in patients treated for NFMA. Design The metabolic syndrome (NCEP-ATP III criteria) was studied in an unselected cohort of 145 NFMA patients (aged 26–88yr, 44% female) in long-term remission after treatment, receiving adequate stable hormone replacement for any pituitary deficiencies. The results were compared to population data of 63,995 Dutch inhabitants by standardization (LifeLines cohort study). Results NFMA patients showed increased risk for reduced HDL-cholesterol (SMR 1.59, 95% CI 1.13–2.11), increased triglyceride levels (SMR 2.31, 95% CI 1.78–2.90) and the metabolic syndrome (SMR 1.60, 95% CI 1.22–2.02), but not for increased blood pressure, waist circumference or hyperglycemia. Preoperative visual field defects independently affected the risk for increased blood pressure (OR 6.5, 95% CI 1.9–22.2), and hypopituitarism was associated with a body mass index - dependent risk for increased waist circumference (OR 1.6, 95% CI 1.2–2.2) and the metabolic syndrome (OR 1.4, 95% CI 1.0–1.9). Conclusions Patients treated for NFMA are increased at risk for developing the metabolic syndrome, mainly due to decreased HDL-cholesterol and increased triglycerides. Risk factors included hypopituitarism and preoperative visual field defects. Hypothalamic dysfunction may explain the metabolic abnormalities, in addition to intrinsic imperfections of hormone replacement therapy. Additional research is required to explore the relation between derangements in circadian rhythmicity and metabolic syndrome in these patients.
References
[1]
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, et al. (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91: 4769–4775. doi: 10.1210/jc.2006-1668
[2]
Dekkers OM, de Keizer RJ, Roelfsema F, Vd Klaauw AA, Honkoop PJ, et al. (2007) Progressive improvement of impaired visual acuity during the first year after transsphenoidal surgery for non-functioning pituitary macroadenoma. Pituitary 10: 61–65. doi: 10.1007/s11102-007-0007-0
[3]
Park P, Chandler WF, Barkan AL, Orrego JJ, Cowan JA, et al. (2004) The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55: 100–106. doi: 10.1227/01.neu.0000126885.71242.d7
[4]
Biermasz NR, Joustra SD, Donga E, Pereira AM, van Duinen N, et al. (2011) Patients previously treated for nonfunctioning pituitary macroadenomas have disturbed sleep characteristics, circadian movement rhythm, and subjective sleep quality. J Clin Endocrinol Metab 96: 1524–1532. doi: 10.1210/jc.2010-2742
[5]
Hochberg I, Hochberg Z (2010) Expanding the definition of hypothalamic obesity. Obes Rev 11: 709–721. doi: 10.1111/j.1467-789x.2010.00727.x
[6]
Knutson KL (2012) Does inadequate sleep play a role in vulnerability to obesity? Am J Hum Biol 24: 361–371. doi: 10.1002/ajhb.22219
[7]
Hardy J (1979) The transsphenoidal surgical approach to the pituitary. Hosp Pract 14: 81–89.
[8]
Ghigo E, Aimaretti G, Corneli G (2008) Diagnosis of adult GH deficiency. Growth Horm IGF Res 18: 1–16. doi: 10.1016/j.ghir.2007.07.004
[9]
Stolk RP, Rosmalen JG, Postma DS, de Boer RA, Navis G, et al. (2008) Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study. Eur J Epidemiol 23: 67–74. doi: 10.1007/s10654-007-9204-4
[10]
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735–2752. doi: 10.1161/circulationaha.105.169404
[11]
Lorenzo C, Williams K, Hunt KJ, Haffner SM (2007) The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30: 8–13. doi: 10.2337/dc06-1414
[12]
de Simone G, Devereux RB, Chinali M, Best LG, Lee ET, et al. (2007) Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care 30: 1851–1856. doi: 10.2337/dc06-2152
[13]
Ryan MC, Fenster Farin HM, Abbasi F, Reaven GM (2008) Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identifying apparently healthy subjects at increased risk of cardiovascular disease. Am J Cardiol 102: 40–46. doi: 10.1016/j.amjcard.2008.02.096
[14]
Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366: 1059–1062. doi: 10.1016/s0140-6736(05)67402-8
[15]
Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423. doi: 10.1136/bmj.326.7404.1423
[16]
Stein EA, Lane M, Laskarzewski P (1998) Comparison of statins in hypertriglyceridemia. Am J Cardiol 81: 66B–69B. doi: 10.1016/s0002-9149(98)00041-1
[17]
Vandenbroucke JP (1982) A shortcut method for calculating the 95 percent confidence interval of the standardized mortality ratio. Am J Epidemiol 115: 304–305.
[18]
Nielsen EH, Lindholm J, Laurberg P, Bjerre P, Christiansen JS, et al. (2007) Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function. Pituitary 10: 67–73. doi: 10.1007/s11102-007-0018-x
[19]
Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, et al. (2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357: 425–431. doi: 10.1016/s0140-6736(00)04006-x
[20]
Nielsen EH, Lindholm J, Laurberg P (2007) Excess mortality in women with pituitary disease: a meta-analysis. Clin Endocrinol (Oxf) 67: 693–697. doi: 10.1111/j.1365-2265.2007.02947.x
[21]
Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW (2006) Central nervous system control of food intake and body weight. Nature 443: 289–295. doi: 10.1038/nature05026
[22]
King BM (2006) The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight. Physiol Behav 87: 221–244. doi: 10.1016/j.physbeh.2005.10.007
[23]
Kreier F, Yilmaz A, Kalsbeek A, Romijn JA, Sauerwein HP, et al. (2003) Hypothesis: shifting the equilibrium from activity to food leads to autonomic unbalance and the metabolic syndrome. Diabetes 52: 2652–2656. doi: 10.2337/diabetes.52.11.2652
[24]
Coomans CP, van den Berg SA, Lucassen EA, Houben T, Pronk AC, et al. (2013) The suprachiasmatic nucleus controls circadian energy metabolism and hepatic insulin sensitivity. Diabetes 62: 1102–1108. doi: 10.2337/db12-0507
[25]
Hofman MA, Swaab DF (1994) Alterations in circadian rhythmicity of the vasopressin-producing neurons of the human suprachiasmatic nucleus (SCN) with aging. Brain Res 651: 134–142. doi: 10.1016/0006-8993(94)90689-0
[26]
Borgers AJ, Alkemade A, Venema HW, Fliers E, Bisschop PH (2012) A history of cranial radiotherapy is associated with a higher visceral to subcutaneous fat ratio in men with pituitary insufficiency. Eur J Endocrinol 166: 619–624. doi: 10.1530/eje-11-1023
Goncharuk VD, van Heerikhuize J, Dai JP, Swaab DF, Buijs RM (2001) Neuropeptide changes in the suprachiasmatic nucleus in primary hypertension indicate functional impairment of the biological clock. J Comp Neurol 431: 320–330. doi: 10.1002/1096-9861(20010312)431:3<320::aid-cne1073>3.0.co;2-2
[29]
Scheer FA, Van Montfrans GA, Van Someren EJ, Mairuhu G, Buijs RM (2004) Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 43: 192–197. doi: 10.1161/01.hyp.0000113293.15186.3b
[30]
Wolden-Hanson T, Mitton DR, McCants RL, Yellon SM, Wilkinson CW, et al. (2000) Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 141: 487–497. doi: 10.1210/endo.141.2.7311
[31]
Borgers AJ, Fliers E, Siljee JE, Swaab DF, Van Someren EJ, et al. (2013) Arginine vasopressin immunoreactivity is decreased in the hypothalamic suprachiasmatic nucleus of subjects with suprasellar tumors. Brain Pathol 23: 440–444. doi: 10.1111/bpa.12016
[32]
Verhelst J, Abs R (2009) Cardiovascular risk factors in hypopituitary GH-deficient adults. Eur J Endocrinol 161 Suppl 1S41–S49. doi: 10.1530/eje-09-0291
[33]
van der Klaauw AA, Biermasz NR, Feskens EJ, Bos MB, Smit JW, et al. (2007) The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol 156: 455–462. doi: 10.1530/eje-06-0699
[34]
Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, et al. (2010) Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab 95: 74–81. doi: 10.1210/jc.2009-1326
[35]
Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, et al. (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab 89: 2192–2199. doi: 10.1210/jc.2003-030840
[36]
Claessen KM, Appelman-Dijkstra NM, Adoptie DM, Roelfsema F, Smit JW, et al. (2013) Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab 98: 352–361. doi: 10.1210/jc.2012-2940
[37]
Zueger T, Kirchner P, Herren C, Fischli S, Zwahlen M, et al. (2012) Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J Clin Endocrinol Metab 97: E1938–E1942. doi: 10.1210/jc.2012-2432
[38]
Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, et al. (2007) Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92: 976–981. doi: 10.1210/jc.2006-2112
